Reverse Cholesterol Transport

AlphaCore Reports Positive Phase 1 Results For New Heart Drug

AlphaCore Pharma announced Tuesday that results from the company’s Phase 1 clinical trial have met the primary endpoint by demonstrating the safety and tolerability of the drug ACP-501 (recombinant human LCAT).

WWJ Newsradio 950–10/09/2012

Follow

Get every new post delivered to your Inbox.

Join 2,368 other followers